Search

Author/Creator Fasching, P A

1. 110PEvaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy. (13th May 2019)

Authors:
Huang, M; Qi, C Z; Ramsey, S; Briggs, A; Zhao, J; Haiderali, A; Karantza, V; Xie, J; Gu, C; Fasching, P A
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 168PValidation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC). (23rd October 2018)

Authors:
Fasching, P A; Laible, M; Weber, K E; Wirtz, R M; Denkert, C; Schlombs, K; Schmatloch, S; Camara, O; Lück, H J; Huober, J; Karn, T; van Mackelenbergh, M T; Marme, F; Müller, V; Schem, C; Stickeler, E; Sahin, U; Loibl, S; Untch, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (23rd October 2018)

Authors:
Untch, M; Jackisch, C; Schneeweiss, A; Schmatloch, S; Aktas, B; Denkert, C; Schem, C; Wiebringhaus, H; Kümmel, S; Rhiem, K; Warm, M; Fasching, P A; Just, M; Hanusch, C; Hackmann, J; Blohmer, J-U; Furlanetto, J; Nekljudova, V; von Minckwitz, G; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 227PEvaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes. (23rd October 2018)

Authors:
Fasching, P A; Laible, M; Weber, K E; Wirtz, R M; Denkert, C; Schlombs, K; Schmatloch, S; Camara, O; Lück, H J; Huober, J; Karn, T; van Mackelenbergh, M T; Marme, F; Müller, V; Schem, C; Stickeler, E; Sahin, U; Loibl, S; Untch, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 243PGermline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. (23rd October 2018)

Authors:
Pohl, E; Schneeweiss, A; Hauke, J; Moebus, V; Furlanetto, J; Denkert, C; Fasching, P A; Hanusch, C; Tesch, H; Weber-Lassalle, N; Müller, V; Rhiem, K; Untch, M; Luebbe, K; Lederer, B; Jackisch, C; Nekljudova, V; Schmutzler, R K; Hahnen, E; Loibl, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. (23rd October 2018)

Authors:
Fasching, P A; Decker, T; Guderian, G; Heim, J; Jackisch, C; Lueck, H-J; Lüftner, D; Marmé, F; Reimer, T; Woeckel, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 331PRibociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3. (23rd October 2018)

Authors:
Jerusalem, G; Fasching, P A; Martín, M; Pivot, X; Petrakova, K; Bianchi, G V; Nusch, A; Sonke, G S; De La Cruz Merino, L; Vagnon, E; Alam, J; Kong, O; Chandiwana, D; De Laurentiis, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. (16th May 2019)

Authors:
Loibl, S; Untch, M; Burchardi, N; Huober, J; Sinn, B V; Blohmer, J -U; Grischke, E -M; Furlanetto, J; Tesch, H; Hanusch, C; Engels, K; Rezai, M; Jackisch, C; Schmitt, W D; von Minckwitz, G; Thomalla, J; Kümmel, S; Rautenberg, B; Fasching, P A; Weber, K
Journal:
Annals of oncology
Issue:
Volume 30:Number 8(2019)
Page Start:
1279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations. Issue 2 (23rd September 2013)

Authors:
Province, M A; Goetz, M P; Brauch, H; Flockhart, D A; Hebert, J M; Whaley, R; Suman, V J; Schroth, W; Winter, S; Zembutsu, H; Mushiroda, T; Newman, W G; Lee, M‐T M; Ambrosone, C B; Beckmann, M W; Choi, J‐Y; Dieudonné, A‐S; Fasching, P A; Ferraldeschi, R; Gong, L
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 95:Issue 2(2014)
Page Start:
216
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗